Networks in Neurology: Insights From a Collaborative CME Experience With Practicing Clinicians Regarding New Agents and Strategies for Multiple Sclerosis
November 30, 2021
November 30, 2022
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by Postgraduate Institute for Medicine (PIM) and Efficient LLC.
This activity is supported by independent educational grants from Biogen, Bristol-Myers Squibb, EMD Serono, and Sanofi.
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of multiple sclerosis specialists, general neurologists, advanced practice neurology professionals, and other healthcare professionals involved in the care of patients with multiple sclerosis.
Multiple sclerosis (MS) management has been evolving at a staggering rate for the past two decades, with nearly a third of the 21 available disease modifying therapies (DMTs) receiving their FDA approvals in just the past few years. To assist practitioners in parsing out the rationale for and clinical utitity of these and other late-stage agents, Efficient surveyed five renowned MS specialists regarding their perspectives on these advances. These results formed the base material for a CME initiative in which those same experts led small groups of clinicians in an eight-week learning experience. The groups participated in a variety of activities including self-study, live discussions, group tasks, and assessments. This activity highlights the most important elements that emerged across the experience including key strategies from experts and insights into where participants are truly struggling that likely resonate with other clinicians.
Upon completion of this activity, participants should be better able to:
- Review the limitations associated with the use of historical S1P receptor modulators and fumarates and how novel formulations address these challenges to determine the appropriate role and patient selection for these agents in clinical practice.
- Discuss the rationale for, experience with, and unique features of agents with novel mechanisms of action and alternative anti-CD20 formulations to help guide their optimal utilization across patients with varied presentations of MS.
- Evaluate published research with and ongoing Phase 3 evaluation of rising BTK inhibitors to discern the potential future role of these agents in the long-term care of patients with MS.
Robert Naismith, MD (Chair)
Clinic Director, John L. Trotter Multiple Sclerosis Center
Director, Multiple Sclerosis Clinical Trials Program
Washington University School of Medicine
St. Louis, Missouri
Erin Longbrake, MD, PhD (Panelist)
Assistant Professor of Neurology
Program Director, Neuroimmunology Fellowship
Director, Clinical Research in Neuroimmunology
New Haven, Connecticut
Darin Okuda, MD (Surveyed Expert)
Professor of Neurology
Director, Neuroinnovation Program
Director, Multiple Sclerosis & Neuroimmunology Imaging Program
UT Southwestern Medical Center
Carrie Hersh, DO, MSc, FAAN (Surveyed Expert)
Assistant Professor of Neurology
Director | Multiple Sclerosis Health and Wellness Program
Cleveland Clinic Mellen Program for Multiple Sclerosis
Lou Ruvo Center for Brain Health
Las Vegas, Nevada
Riley Bove, MD (Surveyed Expert)
Assistant Professor of Neurology
Director of Digital Innovation, UCSF MS and Neuroinflammation Center
UCSF Weill Institute for Neurosciences
San Francisco, California
Eric Klawiter, MD, MSc (Group Leader)
Associate Professor of Neurology
Massachusetts General Hospital/Harvard Medical School
This activity is jointly provided by Postgraduate Institute for Medicine and Efficient LLC.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Efficient LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PIM designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
- Dr. Naismith
- Consulting Fees (e.g., advisory boards): Biogen, Celgene, Genentech, Genzyme, Lundbeck, NervGen, Third Rock Ventures, Viela Bio.
- Dr. Longbrake
- Consulting Fees (e.g., advisory boards): Genentech.
- Dr. Okuda
- Consulting Fees (e.g., advisory boards): Celgene, EMD Serono, Viela Bio.
- Contracted Research : Biogen.
- Dr. Hersh
- Consulting Fees (e.g., advisory boards): Biogen, Bristol-Myers Squibb, EMD-Serono, Genentech, Genzyme, Novartis.
- Fees for Non-CME/CE Services: Biogen, Bristol-Myers Squibb, EMD-Serono, Genentech, Genzyme, Novartis.
- Dr. Bove
- Consulting Fees: Alexion, Biogen, Novartis, Roche Genentech, Sanofi Genzyme.
- Contracted Research: Biogen, Roche Genentech.
- Dr. Klawiter
- Consulting Fees: Banner Life Sciences, Genentech/Roche.
- Contracted Research: Abbvie, Biogen, Genentech/Roche, Genzyme.
The PIM planners and others have nothing to disclose. The Efficient planners and others have nothing to disclose.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Complete the pre- and post-assessment and submit the evaluation form.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
For CME questions please contact: firstname.lastname@example.org